Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS‐SR project.

Autor: Evans, Connor, Shepherd, Lucy, Bryan, Gemma, Fulbright, Helen, Crowther, Scott, Wakeling, Sara, Stewart, Andy, Stewart, Claire, Chisholm, Julia, Gibson, Faith, Phillips, Bob, Morgan, Jessica E.

Publikováno v: International Journal of Cancer; Apr2024, Vol. 154 Issue 7, p1235-1260, 26p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16 , 998.

Autor: Chisholm J; Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton SM2 5PT, UK., Mandeville H; Children and Young People's Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton SM2 5PT, UK., Adams M; Children's Hospital for Wales, Cardiff CF14 4XW, UK., Minard-Collin V; Department of Paediatric Oncology, Gustave Roussy, 75015 Paris, France., Rogers T; Department of Paediatric Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 3NU, UK., Kelsey A; Department of Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK., Shipley J; The Institute of Cancer Research, London SW7 3RP, UK., van Rijn RR; Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam UMC, 1081 HV Amsterdam, The Netherlands., de Vries I; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., van Ewijk R; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., de Keizer B; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Gatz SA; Birmingham Women's and Children's NHS Foundation Trust, Birmingham B15 2TG, UK.; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK., Casanova M; Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy., Hjalgrim LL; University Hospital Copenhagen, DK-2200 Copenhagen, Denmark., Firth C; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK., Wheatley K; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK., Kearns P; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK., Liu W; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK., Kirkham A; Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK., Rees H; Department of Paediatric Oncology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 3NU, UK., Bisogno G; Department of Women and Children's Health, University of Padova, 35122 Padua, Italy., Wasti A; The Institute of Cancer Research, London SW7 3RP, UK., Wakeling S; Alice's Arc Charity, London EC1V 1AW, UK., Heenen D; KickCancer Foundation, 1000 Brussels, Belgium., Tweddle DA; Vivo Biobank, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK., Merks JHM; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands., Jenney M; Children's Hospital for Wales, Cardiff CF14 4XW, UK.

Publikováno v: Cancers [Cancers (Basel)] 2024 Oct 09; Vol. 16 (19). Date of Electronic Publication: 2024 Oct 09.